Showing 130 results
September 2022
-
Media Release
Philippine FDA approves Novartis drug, ribociclib, for advanced breast cancer in males
The Philippine Food and Drug Administration (FDA) has approved ribociclib for the treatment of metastatic breast cancer. Ribociclib in combination with an aromatase inhibitor or fulvestrant… -
Story
Novartis supports the Southeast Asian Breast Cancer Symposium
August 2022
-
Media Release
Alliance and Partnerships for Patient Innovation and Solutions (APPIS) Initiative announces winners of inaugural Innovator Program
The APPIS Innovator Program enables patient organizations across Asia Pacific, Middle East and Africa (APMA) to grow and scale existing patient programs. Winners receive financial support,… -
Media Release
Novartis hails Philippine FDA approval of brolucizumab treatment for age-related macular degeneration in time for Sight Saving Month
The Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wet AMD is the leading cause of severe…
July 2022
-
Media Release
Novartis, Ask Your Derm PH raise awareness on pediatric psoriasis and effective treatments to help children manage symptoms, enjoy life
Psoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help… -
Media Release
Experts encourage women with advanced breast cancer to get tested for PIK3CA mutation to improve treatment outcomes
Genetic mutations affect breast cancer prognosis, making every patient unique. It is important for patients to get tested to find out the specific mutation, and help doctors develop a personalized… -
Media Release
Philippine FDA approves Novartis advanced breast cancer treatment, alpelisib
The Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…
May 2022
-
Media Release
Novartis Philippines launches PIK3CA Testing Program for Breast Cancer
Stakeholder officials signed the formal agreement to implement the Novartis PIK3CA Testing Program for advanced Breast Cancer patients. Photo shows (from left): Ms… -
Media Release
Survey reveals delayed diagnosis, heavy disease burden among Filipinos with axial spondyloarthritis
On average, Filipinos with axial spondyloarthritis (axSpA) are diagnosed 5.8 years after developing the disease. axSpA has significant functional, psychosocial and economic impact on patients,…